1. Examining the Latest Evidence in PAH

3. Background

4. Important Advances in PAH

5. Initial Therapy Determines Follow-Up

6. Treatment Options in PAH

7. Growing Use of Combination Therapy

8. An Evolving Paradigm: From Sequential to Initial Up-front Combination Therapy

9. AMBITION Study

10. Clinical Trial Data vs Registry Data

11. Candidates for Monotherapy

12. Determinants of Initial Treatment for PAH

13. Follow-Up in PAH: Clinical Practice Consistent With Guideline Recommendations

14. Risk Stratification in PAH

15. French Registry: Survival Based on Number of Low-Risk Criteria Achieved at First Evaluation

16. Registry Data Confirm Need for Early Diagnosis and Treatment Intensification

17. French Registry: BNP Subset Analysis

18. Achieving Low-Risk Status in PAH

19. Additional Testing With RHC

20. Weighing Patient Risks and Current Options

21. GRIPHON: Study Design

22. Effect of Selexipag on Primary Composite Endpoint in GRIPHON

23. GRIPHON: Treatment Effect by WHO FC Group

24. TRITON: Triple Up-front Combination Therapy

25. Putting It All Together -- What Do We Know?

26. Faculty Approaches to PAH Treatment

27. Patient-Centered Approach to PAH

28. Conclusion

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)